Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Effects of Vitrectomy on Recurrent Macular Edema due to Branch Retinal Vein Occlusion after Intravitreal Injection of Bevacizumab.

Yunoki T, Mitarai K, Yanagisawa S, Kato T, Ishida N, Hayashi A.

J Ophthalmol. 2013;2013:415974. doi: 10.1155/2013/415974. Epub 2013 Feb 20.

2.

Bevacizumab treatment for acute branch retinal vein occlusion accompanied by subretinal hemorrhage.

Zhao L, Li B, Feng K, Han L, Ma Z, Liu Y.

Curr Eye Res. 2015 Jul;40(7):752-6. doi: 10.3109/02713683.2014.952827. Epub 2014 Oct 20.

PMID:
25330134
3.

25-gauge vitrectomy versus intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion: 1 year follow-up.

Sato T, Sawada K, Iwahashi-Shima C, Bando H, Ikeda T, Emi K.

Ann Acad Med Singapore. 2012 Jul;41(7):294-9.

4.

Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion.

Jaissle GB, Szurman P, Feltgen N, Spitzer B, Pielen A, Rehak M, Spital G, Heimann H, Meyer CH; Retinal Vein Occlusion Study Group.

Graefes Arch Clin Exp Ophthalmol. 2011 Feb;249(2):183-92. doi: 10.1007/s00417-010-1470-2. Epub 2010 Aug 18.

5.

Comparison of natural course, intravitreal triamcinolone, and intravitreal bevacizumab for treatment of macular edema secondary to branch retinal vein occlusion.

Kwon SI, Kim YW, Bang YW, Lee JY, Park IW.

J Ocul Pharmacol Ther. 2013 Feb;29(1):5-9. doi: 10.1089/jop.2011.0249. Epub 2012 Dec 13.

PMID:
23237542
6.

The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions.

Ivanovska Adjievska B, Boskurt S, Orovcanec N, Dimovska-Jordanova V.

Clin Ophthalmol. 2017 Jun 21;11:1183-1190. doi: 10.2147/OPTH.S137380. eCollection 2017.

7.

Pars plana vitrectomy versus three intravitreal injections of bevacizumab for nontractional diabetic macular edema. A prospective, randomized comparative study.

Raizada S, Al Kandari J, Al Diab F, Al Sabah K, Kumar N, Mathew S.

Indian J Ophthalmol. 2015 Jun;63(6):504-10. doi: 10.4103/0301-4738.162602.

8.

Efficacy of intravitreal triamcinolone for the treatment of macular edema secondary to branch retinal vein occlusion in eyes with or without grid laser photocoagulation.

Cakir M, Dogan M, Bayraktar Z, Bayraktar S, Acar N, Altan T, Kapran Z, Yilmaz OF.

Retina. 2008 Mar;28(3):465-72. doi: 10.1097/IAE.0b013e318154b9d1.

PMID:
18327140
9.
10.

Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: a matched study.

Hou J, Tao Y, Jiang YR, Li XX, Gao L.

Chin Med J (Engl). 2009 Nov 20;122(22):2695-9.

PMID:
19951598
11.

Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up.

Wu L, Arevalo JF, Roca JA, Maia M, Berrocal MH, Rodriguez FJ, Evans T, Costa RA, Cardillo J; Pan-American Collaborative Retina Study Group (PACORES).

Retina. 2008 Feb;28(2):212-9. doi: 10.1097/IAE.0b013e3181619bee.

PMID:
18301025
12.

Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.

Ding X, Li J, Hu X, Yu S, Pan J, Tang S.

Retina. 2011 May;31(5):838-45. doi: 10.1097/IAE.0b013e3181f4420d.

PMID:
21293319
13.

Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion.

Higashiyama T, Sawada O, Kakinoki M, Sawada T, Kawamura H, Ohji M.

Acta Ophthalmol. 2013 Jun;91(4):318-24. doi: 10.1111/j.1755-3768.2011.02298.x. Epub 2011 Dec 1.

14.

Combination therapy with intravitreal bevacizumab and macular grid and scatter laser photocoagulation in patients with macular edema secondary to branch retinal vein occlusion.

Yang CS, Liu JH, Chung YC, Chou YB, Hung KH.

J Ocul Pharmacol Ther. 2015 Apr;31(3):179-85. doi: 10.1089/jop.2014.0069. Epub 2015 Feb 25.

PMID:
25715024
15.

Comparative study of combined bevacizumab/targeted photocoagulation vs bevacizumab alone for macular oedema in ischaemic branch retinal vein occlusions.

Tomomatsu Y, Tomomatsu T, Takamura Y, Gozawa M, Arimura S, Takihara Y, Inatani M.

Acta Ophthalmol. 2016 May;94(3):e225-30. doi: 10.1111/aos.12721. Epub 2015 May 19.

16.

Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.

Solaiman KA, Diab MM, Abo-Elenin M.

Retina. 2010 Nov-Dec;30(10):1638-45. doi: 10.1097/IAE.0b013e3181e1ed07.

PMID:
20838357
17.

Influence of retinal ischemia on macular function after pars plana vitrectomy for macular edema with branch retinal vein occlusion.

Noma H, Shimada K, Mimura T.

Int Ophthalmol. 2013 Dec;33(6):677-86. doi: 10.1007/s10792-013-9762-2. Epub 2013 Mar 29.

PMID:
23539479
18.

Intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion: 12-month results.

Thapa R, Maharjan N, Paudyal G.

Clin Ophthalmol. 2012;6:1057-62. doi: 10.2147/OPTH.S30555. Epub 2012 Jul 12.

19.

Grid photocoagulation combined with intravitreal bevacizumab for recurrent macular edema associated with retinal vein occlusion.

Ogino K, Tsujikawa A, Murakami T, Muraoka Y, Kurashige Y, Yoshimura N.

Clin Ophthalmol. 2011;5:1031-6. doi: 10.2147/OPTH.S22923. Epub 2011 Jul 26.

20.

Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results.

Demir M, Oba E, Gulkilik G, Odabasi M, Ozdal E.

Clin Ophthalmol. 2011;5:745-9. doi: 10.2147/OPTH.S19279. Epub 2011 Jun 3.

Supplemental Content

Support Center